Agilent Technologies and UC San Diego to Sponsor Lecture Series

Nobel Laureate Randy Schekman to Present on May 7: “Genes and Proteins That Control Secretion and Autophagy”

Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--

Agilent Technologies Inc. (NYSE:A) today announced the first in a series of public lectures that will be sponsored in collaboration with the University of California, San Diego.

On Wednesday, May 7, Dr. Randy Schekman, the 2013 winner of the Nobel Prize in Physiology or Medicine, will present a lecture titled, “Genes and Proteins that Control Secretion and Autophagy.”

Dr. Schekman’s presentation will focus on how a specific cellular mechanism can affect cancer, infectious diseases and other medical conditions. He will highlight his work on the development and analysis of cell-free reactions that replicate the lipidation of the major peripheral autophagosomal protein (LC-3), which plays a primary role in autophagy. Autophagy is the cellular mechanism responsible for the degradation of unnecessary and dysfunctional cellular components. If properly regulated, autophagy can inhibit the growth of cancer cells and cells associated with other infectious diseases and medical conditions.

“I am pleased to be a part of this lecture series to share my research group’s contributions in the area of protein secretion and our new findings on the connection between secretion and the process of autophagy,” said Dr. Schekman, who currently serves as an investigator at the Howard Hughes Medical Institute and a professor of cell and developmental biology at UC Berkeley. “These pathways are essential to normal cell growth and play direct roles in human disease.”

“We are honored to partner with UC San Diego in this program and are privileged to welcome Dr. Schekman as the first speaker in the series,” said Agilent’s Björn Ogren, a product specialist for mass spectrometry. “Dr. Schekman’s findings have solved a long-standing mystery of cell biology and provided the foundation that underpins modern insulin production.”

This free event is open to the public. Dr. Schekman’s presentation will begin at 4 p.m. PDT on Wednesday, May 7, at the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences auditorium.

“UCSD is thrilled to host this new lecture series sponsored by Agilent and absolutely delighted that professor Schekman will be the inaugural lecturer,” said Dr. Neal Devaraj, a professor of Chemistry and Biochemistry at UC San Diego.

For more information and to register, please visit: Agilent Lecture Series – UC San Diego. View a copy of Dr. Schekman’s lecture abstract here.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.

On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

Contact:
Agilent Technologies Inc.
Susan Berg, +1 408-553-7093
susan_berg1@agilent.com

View Comments (0)